REGISTER BY AUGUST 16 TO SAVE $700

December 2-4, 2019 | Boston, USA

www.rna-drugdiscovery.com

2nd RNA-TARGETED DRUG DISCOVERY SUMMIT

Successfully Optimize Target Validation, Improve Drug-Like Properties & Accelerate the Translation of Selective & Bioactive RNA Targeted Small Molecules into Human Clinical Trials

Expert Speakers Include:

Kevin Weeks
Founder of Ribometrix; Professor of Chemistry
University of North Carolina

Frank Slack
Co-Founder of Twentyeight-Seven Therapeutics; Professor
BIDMC

Kathryn McCabe
Sr. Director of Business Development
Eli Lilly

Jane Withka
Director & Collaboration Lead
Pfizer Worldwide R&D

Christopher Barbieri
Senior Investigator
Bristol-Myers Squibb

Jennifer Petter
Founder & CSO
Arrakis Therapeutics

Yochi Slonim
Co-Founder & CEO
Anima Biotech

Gerhard Mueller
CSO
Gotham Therapeutics

Margaret Porter Scott
VP, Biochemical & Cellular Pharmacology
Genentech

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com

hansonwade

Finally Drug the "Undruggable" RNA

Successfully Optimize Target Validation, Improve Drug-Like Properties & Accelerate the Translation of Selective & Bioactive RNA Targeted Small Molecule Therapeutics into Human Clinical Trials

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the **2nd RNA- Targeted Drug Discovery Summit** returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to overcome unique discovery and development challenges associated with novel RNA targeted small molecule therapeutics and achieve their seemingly limitless potential.

For the 2nd year, network with the KOLs and RNA pioneers, to gain a comprehensive understanding on how to **translate the first generation of RNA targeted small molecules into the clinic, delve into the exciting field of epitranscriptomics** and stimulate discussion on how to **successfully target RNA via RNA- modifying enzymes and interfering with RNA-protein interactions.**

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, join the **2nd RNA- Targeted Drug Discovery Summit – the only industry and translational focused conference dedicated to advancing pioneering RNA targeted small molecule therapeutics** to re-define the undruggable nature of RNA once and for all.

What are our speakers looking forward to at this summit?

"Potentially the best collection of speakers and thought leaders pursuing RNA with small molecules"

Jennifer Petter- Founder & CSO- **Arrakis Therapeutics**

"I am glad to be part of this symposium. It's a great opportunity to learn and share experience with leaders in this fascinating, promising and growing area of drug discovery"

Pramod Pandey - Principal Scientist - **Merck Research Labs, Exploratory Science Center**

Why Attend the 2nd RNA- Targeted Drug Discovery Summit 2019?

Expand your knowledge of RNA structure, function & role in disease with insights from **Beth Israel Deaconess Medical Center, University of North Carolina & Northwestern University**

Successfully target RNA via interfering with RNA-protein interactions/ epitranscriptomics with knowledge from **Storm Therapeutics, Accent Therapeutics & Gotham Therapeutics**

Advance identification & validation of viable RNA target sites for therapeutic intervention with input from **Bristol-Myers Squibb, PTC Therapeutics & Merck**

Overcome binding, selectivity & drug-like challenges of small molecules targeting RNA with expertise from **Pfizer, Novartis & Weill Cornell Medicine**

Join the momentum to reverse the undruggable nature of RNA and seize the enormous therapeutic potential with R&D and strategic insights from **Anima Biotech, Arrakis Therapeutics & Eli Lilly**

YOUR EXPERT SPEAKERS

Jane Withka
Director & Collaboration Lead
Pfizer Worldwide R&D

Samie R. Jaffrey
Co-Founder of Gotham Therapeutics; Professor of Pharmacology
Weill Cornell Medicine

Jennifer Petter
Founder & CSO
Arrakis Therapeutics

Richard Gregory
Co-Founder of Twentyeight-Seven Therapeutics; Professor
Boston Children's Hospital/Harvard Medical School

Kathryn McCabe
Senior Director of Business Development-Emerging Technology & Innovation
Eli Lilly

Yochi Slonim
Co-Founder & CEO
Anima Biotech

Margaret Porter Scott
VP, Biochemical & Cellular Pharmacology
Genentech

Frank Slack
Co-Founder of Twentyeight-Seven Therapeutics; Professor of Pathology
Beth Israel Deaconess Medical Center

Razvan Nutiu
Senior Investigator
Novartis

Wesley Blackaby
VP, Chemistry
Storm Therapeutics

Kevin Weeks
Founder of Ribometrix; Professor of Chemistry
University of North Carolina

Thomas Hermann
Professor of Chemistry & Biochemistry; Associate Dean of Physical Sciences
University of California, San Diego

Martin Pettersson
Research Fellow
Pfizer

George A. Calin
Professor, Department of Experimental Therapeutics
The University of Texas MD Anderson Cancer Center

Johan Pontin
Founder & Former CEO
The RNA Medicines Company

Christopher Barbieri
Senior Investigator
Bristol-Myers Squibb

Gerhard Mueller
CSO
Gotham Therapeutics

Ann Boriack-Sjodin
VP, Molecular Discovery
Accent Therapeutics

Christopher R. Trotta
VP, Biology
PTC Therapeutics

Pramod Pandey
Principal Scientist
Merck Research Labs Exploratory Science Center

Gabriele Varani
Professor of Chemistry
University of Washington

John Schneekloth
Senior Investigator
National Cancer Institute

Julius B. Lucks
Associate Professor
Northwestern University

Pawel Sledz
Senior Scientist & Project Manager
University of Zurich

John Moffat
Senior Scientist, Biochemical & Cellular Pharmacology
Genentech

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED IN THE SUMMIT?

Understanding the impact of RNA modifications on RNA function will require a toolkit of potent and selective molecules that can be used to test biological hypotheses and understand the role of RNA modifying proteins in normal and disease states. I look forward to presenting our own data as well as hearing the successes and challenges of others that are also at the forefront of this novel area of drug discovery

Ann Boriack-Sjodin
VP, Molecular Discovery
Accent Therapeutics

RNA-targeted drug discovery has only recently re-emerged as a focus in the pharmaceutical research. As such, it is rare to be able to find individuals with expertise in moving these drug discovery programs toward the clinic. The meeting will be a great opportunity to bring this community together and to hear about the latest progress made by key opinion leaders throughout academia, biotech, and pharma

Christopher Barbieri
Senior Investigator
Bristol-Myers Squibb

The RNA Targeted Drug Discovery Summit provides a unique opportunity to bring together researchers in academia and industry working to understand RNA biology concepts and experimental approaches relevant to targeting RNA-mediated processes with small molecules, driving this field forward

Christopher R. Trotta
VP, Biology
PTC Therapeutics

The first edition of the meeting provided an exceptional opportunity to meet not just academics, but especially representatives from industry and the investor community. These opportunities continue to be of great value as we spin-off the academic work we have conducted into a fully-fledged start-up

Gabriele Varani
Professor of Chemistry
University of Washington

This meeting is an excellent opportunity to interface with industry members who are working hard to translate fundamental scientific findings into impactful new treatments

Julius B. Lucks
Associate Professor
Northwestern University

PRE-CONFERENCE WORKSHOP DAY
MONDAY | DECEMBER 2, 2019

Workshop A — 9.30 - 11.30

Empowering RNA Drug Target Validation: *"An Essential Initial Step for Every Drug Discovery Effort"*

(miR-21 and its role in cancer will be used as a case study for the discussion)

How do we ensure that the RNA we are targeting is a high value drug target?

As drug hunters how do we validate a RNA as a drug target? Translational medicine in the area of RNA Medicine is still in its nascency, there are very few examples in literature that gives us strong confidence of the role RNA plays in disease.

- How do we as drug hunters in the industry collaborate best with academic medical research institutes to accelerate the research in translational medicine to best elucidate the role of RNA in disease?
- What are the best tools to elucidate the role of RNA in disease?

Drug discovery on target

Once we validate a specific RNA as a drug target how do we generate the appropriate drug like tool molecules to ensure we guide our drug discovery effort with specificity? Drug discovery on Target is critical and always a challenge, particularly with small molecules that are promiscuous in their nature.

Mechanism of Action; are CRISPR and oligonucleotides appropriate control tools when you develop small molecules targeting RNA?

Cell based systems for screening molecules, compare and contrast, do they correlate?

- 2D Cell Cultures vs. 3D Cell Cultures
- 3D Organoids vs. Mouse Models

Workshop Leader:

Johan Pontin
Founder & Former CEO
The RNA Medicines Company

Workshop B — 12.30 – 14.30

Exploring Drug Discovery Approaches to RNA

Shifting the paradigm from targeting protein to targeting RNA requires rethinking several aspects of drug discovery including target selection, lead discovery, assays to support lead optimization as well as in vivo pharmacodynamic markers. This workshop will provide an overview of all the published approaches to drugging RNA as well as highlight key technologies that may prove useful for initiating new programs. This will be an interactive workshop where participants are welcome to share any learnings as well as discuss and debate the best directions to take in this highly challenging and exciting new area. A case study of one company's approach to drugging RNA will be highlighted.

Key questions the workshop aims to address:

- How should novel targets be selected/discovered for RNA-targeted approaches?
- What mechanisms are possible or likely to work? Discuss the various known approaches of affecting splicing, 5' UTR interference to decrease transcription, binding to mRNA etc?
- What are the pitfalls when transitioning from targeting protein to targeting RNA (what mindsets need to change)?
- What are the key technologies useful for drugging RNA? What is the role of structure-based design, computational methods, biophysics, cell-based assays etc?
- What are appropriate pharmacodynamic (PD) markers for RNA targeted therapy and what level of PD can we expect (partial or full PD responses?).

Workshop Leaders:

Margaret Porter Scott
VP, Biochemical & Cellular Pharmacology
Genentech

John Moffat
Senior Scientist, Biochemical & Cellular Pharmacology
Genentech

Workshop C — 15.00 - 17.00

Enabling Targeting of Non-Coding RNAs with Small Molecules: Why, How and to Whom?

One of the most fascinating discoveries in molecular oncology has been that cancer represents a disease in which genetic alterations in protein-coding, but also in non-coding genes complement each other. MicroRNAs (miRNAs) are a type of non-coding RNA (ncRNA) transcripts that can regulate gene expression primarily by disrupting messenger RNA (mRNA) translation and/or stability, or alternatively by modulating the transcription of target mRNAs. For the last decade, miRNAs have shown to be pivotal characters of every single one of the cancer hallmarks. Profiling studies have proven the significance of identifying over-expressed miRNAs (oncomiRs) causative of the activation of oncogenic pathways that lead to malignancy. Due to their crucial role in cancer, it has become a challenge to develop efficient miRNA-inhibiting strategies such as antagomiRs, locked nucleic acids or antisense oligonucleotides. However, to this date, the accessible delivery agents and their pharmacokinetic/pharmacodynamic properties are not ideal. Thus, there is an urgent, unmet need to develop miRNA-based inhibitory therapeutics. Herein we will discuss the advantages and challenges of a novel therapeutic strategy: the use of small molecule inhibitors to target specific miRNAs (SMIRs), as well as the new concept of small molecules "hijacking" by oncogenic miRNAs.

- Why develop SMIRs against oncogenic miRNAs?
- What is the specific spectrum of patients to be targeted?
- What is the small molecules "hijacking" by oncogenic miRNAs?
- What are the best options to develop such SMIRs?
- Is RNA therapeutics in cancer still a viable option?

Workshop Leader:

George A. Calin
Professor, Department of Experimental Therapeutics
The University of Texas MD Anderson Cancer Center

"At this summit, I hope to learn more about how far the competition in the epitranscriptomic space has progressed over the last year. I also hope to see new convincing target validation work allowing for a better pick of disease-relevant drug targets. Finally, I look forward to connecting personally with colleagues in the field and increase my professional network"

Gerhard Mueller, CSO, **Gotham Therapeutics**

CONFERENCE DAY ONE
TUESDAY | DECEMBER 3, 2019

	7.00	**Registration & Networking Coffee**
Jane Withka Director & Collaboration Lead **Pfizer Worldwide R&D**	**8.20**	**Chair's Opening Remarks**

Drugging the Undruggable RNA: Expanding the Knowledge of RNA Structure, Function & Role in Disease

Kevin Weeks Founder of Ribometrix; Professor of Chemistry **University of North Carolina**	**8.30**	**Structure-Based Discovery of New Functions in Large RNAs** • New technologies enable discovery of functional RNA structures • Focusing on complex 3D RNA structures offers a compelling approach for drug discovery
Frank Slack Co-Founder of Twentyeight-Seven Therapeutics; Professor of Pathology **Beth Israel Deaconess Medical Center**	**9.00**	**MicroRNA-Based Therapeutics in Cancer** • Learn about the connection of microRNAs and cancer • Learn about delivery of microRNAs as therapeutics • Learn about mouse models of microRNA over-expression
Julius B. Lucks Associate Professor **Northwestern University**	**9.30**	**Nascent RNA Structures: A Potential Gold Mine for Drug Targets** • RNAs fold dynamically every time they are synthesized in the cell during transcription • There appear to be general principles that govern RNA cotranscriptional folding pathways such as the prevalence of kinetically trapped out-of-equilibrium folded states • These states may be ideal targets for small molecule drugs that can trap RNAs and disrupt their function
	10.00	**Speed Networking & Morning Refreshments**

The Era of Epitranscriptomics: Successfully Targeting RNA via Interfering with RNA-Protein Interactions

Richard Gregory Co-Founder of Twentyeight-Seven Therapeutics; Professor **Boston Children's Hospital/Harvard Medical School**	**11.00**	**Emerging Role of RNA Methylation in Cancer** • Our focus is on understanding the mechanisms and role of RNA methylation in cancer • Of particular relevance is our recent breakthrough findings that provide the very first functional evidence linking the N6-methyladenosine (m^6A) modification of mRNAs with cancer and provides the first insights into the role and mechanism of the m^6A methyltransferase METTL3 in the control of oncogene mRNA translation • Our lab uncovered the very first m^6A epitranscriptome in human tumor samples and our pioneering studies pave the way for the emergence of the epitranscriptome and cancer field • We also developed new methods to map the N7-methylguanosine (m^7G) modification of tRNAs by METTL1 and will present our latest findings on the role of METTL1 in oncogenic transformation

Wesley Blackaby
VP, Chemistry
Storm Therapeutics

11.30 Drugging RNA Modifying Enzymes

- An outline of the progress made by Storm in drugging RNA modifying enzymes
- This will include the technologies we are utilizing and the supporting data
- An update on our latest progress

Ann Boriack-Sjodin
VP, Molecular Discovery
Accent Therapeutics

12.00 RMP-Targeted Cancer Drug Discovery

- RNA modifying proteins (RMPs) represent a large class of novel targets for oncology and other disease indications that can be targeted with small molecule inhibitors
- Accent has prioritized drug discovery efforts on METTL3, an m^6A RNA methyltransferase implicated in AML and multiple solid tumor indications
- Potent, selective inhibitors of METTL3 have been identified and characterized in biochemical and cellular assays with correlations seen between biochemical potency, m^6A depletion and cell proliferation

Gerhard Mueller
CSO
Gotham Therapeutics

12.30 Epitranscriptomic 'm6A' Target Space: When & Why to go Biophysical with Your Target

- Small-molecule drug discovery projects are pursued within Gotham
- Inhibitors and Antagonists for m6A-writing and -erasing enzymes, as well as for reader domains are being developed
- Intensive use of complementary biophysical techniques such as SPR, Xray, protein NMR allows for deeper understanding of exact molecular mechanisms of action, and thus provides the rationales for choosing best possible chemical matter

13.00 Networking Lunch

Advancing Identification & Validation of Viable RNA Target Sites for Therapeutic Intervention

George A. Calin
Professor, Department of Experimental Therapeutics
The University of Texas MD Anderson Cancer Center

14.00 Targeting Non-Coding RNAs with Small Molecules: From Theory to Medical Practice

- Why targeting non-coding RNAs with small molecules?
- Who are the patients to be targeted?
- What are the non-coding RNAs to be targeted?

Christopher Barbieri
Senior Investigator
Bristol-Myers Squibb

14.30 Identifying Inhibitors of Dicer Processing of Specific Pre-miRNA Motifs

- Small non-coding RNA molecules such as microRNA play key roles in the regulation of many essential biological processes making them intriguing targets for therapeutic intervention
- Dicer endonuclease processing of pre-microRNA to mature miRNA is a potential node for modulation of gene silencing, but the essential activity of Dicer and the small size and minimal tertiary structure of specific pre-miRNA make them difficult targets for rational drug design strategies
- We are developing new methods for identifying and characterizing inhibitors of processing of specific pre-miRNA sequences by Dicer

Christopher R. Trotta
VP, Biology
PTC Therapeutics

15.00 Targeting Pre-mRNA Splicing to Discover Novel Small Molecule Therapeutics

- snRNP recruitment and splice site recognition is driven by RNA-RNA interactions and forms the basis of pre-mRNA splicing
- The diversity of sequences found at splice sites throughout the human genome provide unique potential drug targets and have led to the discovery of small molecule splicing modifiers for clinical use in genetic diseases such as spinal muscular atrophy and familial dysautonomia
- Based on this work, we have built platform technologies that enable the discovery of additional splicing modifiers for therapeutically relevant splicing events

	15.30	**Afternoon Refreshments & Networking**
Pramod Pandey Principal Scientist **Merck Research Labs Exploratory Science Center**	16.00	**Unlocking RNA Biology: Platform to Study RNA-Protein Interactions to Identify Novel Targets for Small Molecule Discovery** • A large fraction of the genome is transcribed into non-coding RNAs and many of these have been implicated in influencing diseases • We are studying these in the context of diseases, relating to barrier function/ dysfunction • Towards that goal, we are developing chemical biology tools to study the RNA-protein interactions and find novel targets for small molecule drug discovery
Thomas Hermann Professor of Chemistry & Biochemistry; Associate Dean of Physical Sciences **University of California, San Diego**	16.30	**Exploration of Fragment Ligand Binding at a Viral Noncoding RNA Target** • Conserved noncoding RNA motifs in viral genomes provide opportunities as targets for the development of viral inhibitors with a high barrier to resistance development • I will discuss the discovery of a target for viral translation inhibitors in the internal ribosome entry site (IRES) RNA of the hepatitis C virus (HCV) • A structure-guided approach was used to discover drug-like fragments for the development of antiviral compounds
Pawel Sledz Senior Scientist & Project Manager **University of Zurich**	17.00	**Structure- & Fragment-Based Development of Small Molecules Targeting RNA-Modifying Proteins & Protein-RNA Interactions Involved in Epitranscriptomic Regulation** • Covalent post-transcriptional modifications of RNA by RMPs constitute additional layer of gene expression regulation; malfunctions of this machinery have been implicated in cancer • Epitranscriptomic modifications alter the properties and dynamics of modified transcripts and expose them to modification-dependent protein-RNA interactions (PRI) with different reader proteins • We demonstrate that both RMPs and PRIs involved in epitranscriptomics modifications can be targeted with small molecules; their early development will be discussed
	17.30	**Chair's Closing Remarks & End of Day One**

"Targeting RNA with small molecules has the potential to open up new target space and alternative intervention points for previously undruggable targets of high value. This conference will be a good opportunity to understand recent developments in this emerging field"

Martin Pettersson, Research Fellow, **Pfizer**

CONFERENCE DAY TWO
WEDNESDAY | DECEMBER 4, 2019

8.30 Coffee & Networking

Jane Withka
Director & Collaboration Lead
Pfizer Worldwide R&D

8.55 Chair's Opening Remarks

Optimizing Discovery & Design Strategies to Target RNA: Overcoming Binding, Selectivity & Drug-Like Challenges

Samie R. Jaffrey
Co-Founder Gotham Therapeutics; Professor of Pharmacology
Weill Cornell Medicine

9.00 Imaging and Assaying Selective Binding of Small Molecules Binding to RNA

- Small molecule target engagement on RNA can be imaged in real-time
- Disease-relevant RNA sequences can be converted into fluorescent sensors for detecting small molecule binding

Gabriele Varani
Professor of Chemistry
University of Washington

9.30 Small Drug-Like Molecules Target Non-Coding RNA with nM Affinity

- A delve into the discovery of drug-like (Lipinski) molecules that bind to non-coding RNAs with low nanomolar affinity
- Structure-based design methods can be used to rapidly improve their affinity and specificity
- These molecules demonstrate specific activity in biochemical and cellular assays

John Schneekloth
Senior Investigator
National Cancer Institute

10.00 Targeting Structurally and Functionally Diverse Nucleic Acids with Drug-Like Small Molecules

- Our laboratory uses a Small Molecule Microarray (SMM) screening approach to profile and identify the RNA-binding properties of small molecules
- Drug-like small molecules are capable of both selectively binding and modulating the function of regulatory RNAs in the cell
- High resolution structural analysis by NMR and X-Ray crystallography is key to establishing a basis for both mechanism of action and molecular recognition

10.30 Morning Refreshments & Networking

Accelerating Robust Translation of Direct & Bioactive RNA Targeted Small Molecules

Yochi Slonim
Co-Founder & CEO
Anima Biotech

11.00 Translation Control Therapeutics: Discovery of Small Molecule Drugs that Specifically Control mRNA Translation into Proteins

- The novel target space of mRNA translation regulation
- Discovery of small molecule drugs that selectively control mRNA translation
- Anima Biotech: bi-directional and tissue selective translation controlling drugs

Jennifer Petter
Founder & CSO
Arrakis Therapeutics

11.30 Drugging RNA with Small Molecules

- Our mission is to render all structured RNA druggable with orally available small molecules
- Structure ID, functional biology, and screening are all on that critical path
- New chemical biology establishes the connection of RNA binding with pharmacology

Martin Pettersson
Research Fellow
Pfizer

12.00 Identification of Small Molecules that Promote Exon 10 Skipping in MAPT Pre-mRNA

- Direct targeting of RNA with small molecules have the potential to expand target space
- This presentation will describe a collaboration with Prof. Matt Disney at Scripps, Florida: Using the Informa lead-generation platform followed by virtual screening and hit expansions, small molecule leads have been identified that demonstrate dose-dependent skipping of exon 10 in MAPT pre-mRNA in cell-based assays
- Efforts to understand target-engagement and binding mode will also be highlighted

12.30 Networking Lunch

Razvan Nutiu
Senior Investigator
Novartis

13.30 Modulation of RNA Biology with Small Molecules

- Gene expression is a complex process that involves multiple mRNA regulation events, such as transcription, splicing, miRNA regulation and translation
- mRNA processing is controlled through interactions between RNA structures and RNA binding proteins
- We aim to identify RNA / protein interactions critical to disease and to modulate them with small molecules

14.00 Panel Discussion: Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities

- How to establish strategies & standards to provide clear guidance on how to intentionally target RNA with small molecules?
- How mRNA and its regulatory mechanisms can enable new strategies against previously undruggable targets? View of the right approach in this vast, novel target space.
- Partnering with pharma: Strategies for emerging platform companies in the RNA field for effective partnering

Moderator:

Jane Withka
Director & Collaboration Lead
Pfizer Worldwide R&D

Panelists:

Yochi Slonim
Co-Founder & CEO
Anima Biotech

Kathryn McCabe
Senior Director of Business Development-Emerging Technology & Innovation
Eli Lilly

Jennifer Petter
Founder & CSO
Arrakis Therapeutics

Christopher Barbieri
Senior Investigator
Bristol-Myers Squibb

14.45 Interactive Round Table Discussions

Our breakout roundtables will allow you to have more intimate and open discussions on some of the hottest topics and key areas of debate. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

What are the clinical indications where small molecule RNA therapeutics can be applied?

What translational challenges do we foresee before the first RNA targeted small molecule goes into clinical development?

How to effectively probe RNA methylation biology with small molecules to get potent and selective chemical matters?

15.30 Chair's Closing Remarks & Close of the 2nd RNA- Targeted Drug Discovery Summit 2019

BECOME A COMMERCIAL PARTNER

100+ ATTENDEES

7+ HOURS OF DEDICATED NETWORKING

3 INTERACTIVE WORKSHOPS

20+ REAL WORLD CASE STUDIES

Why Attend RNA- Targeted Drug Discovery Summit 2019?

1. Benchmark against the latest findings of the field of RNA targeted small molecules and join the momentum in re-defining the 'undruggable' nature of RNA
2. Advance your understanding of the impact of RNA modifications on RNA function as the field of epitranscriptomics gains momentum
3. Maximize your success rate by getting the latest update on the different strategies currently under investigation and robustly translate the 1st generation of RNA targeted small molecules into the clinic

WHY SPONSOR?

Benefit from Market Intelligence
Drugging the previously undruggable RNA targets opens tremendous opportunity to address the current unmet clinical need. Hear how and where pharmaceutical giants are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly

Raise Brand Awareness
Benefit from pre and post conference exposure to our drug discovery KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers

Generate Commercial Collaborations
Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event

Position Yourself as an Industry Expert
With the emergence of biotech companies focused on developing RNA targeted small molecule therapies, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision makers in the field

Meet and Network with Industry Pioneers
With a room full of drug developers looking to see how they can effectively translate their exciting early discovery efforts into safe and effective therapeutics, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions

SENIORITY



- C-Suite & VP Level: 60%
- Director Level: 20%
- Other: 20%

COMPANY BY TYPE



- Large pharma & Biotech
- Academic institutions
- Technology Companies

GET INVOLVED



Bashir Langhi
Partnerships Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.rna-drugdiscovery.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

1. **SAVE** valuable time and resources by learning how the leading companies in the space are advancing their RNA targeted small molecule therapeutics
2. **GAIN** first-hand insights on challenges and strategies on how to robustly translate promising RNA targeted small molecule discoveries into clinical development and increase your success rate
3. **FORM** lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively advancing the field and seeking the best solutions, in an intimate environment

SECURE YOUR PLACE

Industry Pricing	Register & Pay before Friday, August 16th **(Save $700!)**	Standard Prices
Full Access (Conference + Workshop Day)	$3,299	$3,999
Conference + One Workshop	$2,799	$3,499
Conference Only	$2,199	$2,899

Academic Pricing	Register & Pay before Friday, August 16th **(Save $420!)**	Standard Prices
Full Access (Conference + Workshop Day)	$1,979	$2,399
Conference + One Workshop	$1,679	$2,099
Conference Only	$1,319	$1,739

Team Discounts*

10% discount – 3 delegates
15% discount – 4 delegates
20% discount – 5 delegates

Please note that discounts are only valid when three or more delegates from one industry company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

VENUE

Westin Copley Place
10 Huntington Avenue, Boston, Massachusetts 02116 USA
For further information or assistance, please visit www.marriott.co.uk/hotels/travel/boswi-the-westin-copley-place-boston/

Code: 000